Targeting lymphocyte co-stimulation: From bench to bedside

Autoimmunity

Volumn 43, Issue 7, 2010, Pages 514-525

  Felix, Nathan J ^a   Suri, Anish ^a   Salter Cid, Luisa ^a   Nadler, Steven G ^a   Gujrathi, Sheila ^a   Corbo, Michael ^a   Aranda, Richard ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

abatacept; autoimmunity; co stimulation; lymphocyte; T cell

Indexed keywords

ABATACEPT; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; OX40 LIGAND; T LYMPHOCYTE RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOCYTE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TARGET CELL; THROMBOCYTOPENIC PURPURA;

ANIMALS; AUTOIMMUNITY; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 77958020886     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003674741     Document Type: Review

References (100)

1. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today 1990; 11(6):211-216.
2. Ledbetter JA, Imboden JB, Schieven GL, Grosmaire LS, Rabinovitch PS, LindstenT, Thompson CB, June CH. CD28 ligation in T-cell activation: Evidence for two signal transduction pathways. Blood 1990;75(7):1531-1539.
3. Schwartz RH, Mueller DL, Jenkins MK, Quill H. T-cell clonal anergy. Cold Spring Harb Symp Quant Biol 1989; 54(pt 2):605-610.
4. Thompson CB, Lindsten T, Ledbetter JA, Kunkel SL, Young HA, Emerson SG, Leiden JM, June CH. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc Natl Acad Sci USA 1989;86(4):1333-1337.
5. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB. Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1(6): 501-508.
6. Damle NK, Linsley PS, Ledbetter JA. Direct helper T-cell-induced B-cell differentiation involves interaction between T-cell antigen CD28 and B-cell activation antigen B7. Eur J Immunol 1991;21(5):1277-1282.
7. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 1991;174(3):561-569.
8. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J, Ledbetter JA, Linsley PS. Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177(1):165-173.
9. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3(5):541-547.
10. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Griesser H, Mak TW. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270(5238):985-988.
11. Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006;24(1): 65-97.
12. Butte MJ, Pena-Cruz V, Kim MJ, Freeman GJ, Sharpe AH. Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45(13):3567-3572.
13. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4\+ CD25\+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12(4):431-440.
14. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 1992;257(5071):789-792.
15. Turka LA, Linsley PS, Lin H, Brady W, Leiden JM, Wei RQ, Gibson ML, Zheng XG, Myrdal S, Gordon D, Bailey T, Bolling SF, Thompson CB. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 1992;89(22):11102-11105.
16. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest 1995; 96(2):987-993.
17. Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur J Immunol 1996;26(10):2320-2328.
18. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265(5176):1225-1227.
19. Racke MK, Scott DE, Quigley L, Gray GS, Abe R, June CH, Perrin PJ. Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis. J Clin Invest 1995;96(5):2195-2203.
20. Arima T, Rehman A, Hickey WF, Flye MW. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis. J Immunol 1996;156(12):4916-4924.
21. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995;181(3):1145-1155.
22. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK. Blockade of CD28 during in vitro activation of encephalito-genic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999;163(3): 1704-1710.
23. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, Anderson D, Cowan S, Price K, Naemura J, Emswiler J, Greene J, Turk LA, Bajorath J, Townsend R, Hagerty D, Linsley PS, Peach RJ. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transpl 2005;5(3):443-453.
24. Davis PM, Abraham R, Xu L, Nadler SG, Suchard SJ. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J Rheumatol 2007;34(11): 2204-2210.
25. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(8):2263-2271.
26. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353(11):1114-1123.
27. Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, Teng J, Kremer JM. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67(8):1084-1089.
28. Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: A histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68(7):1220-1227.
29. Weisman MH, Durez P, Hallegua D, Aranda R, Becker JC, NuamahI, VratsanosG,Zhou Y, Moreland LW. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. J Rheumatol 2006;33(11): 2162-2166.
30. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva CA, Abud-Mendoza C, Burgos-Vargas R, Gerloni V, Melo-Gomes JA, Saad-Magalhaes C, Sztajnbok F, Goldenstein-Schainberg C, Scheinberg M, Penades IC, Fischbach M, Orozco J, Hashkes PJ, Hom C, Jung L, Lepore L, Oliveira S, Wallace CA, Sigal LH, Block AJ, Covucci A, Martini A, Giannini EH. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372(9636): 383-391.
31. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103(9): 1243-1252.
32. Mease P, Genovese MC, Ritchlin C, Wollenhaupt J, Tak PP, Kivitz A, Gladstein G, Bahary O, Kelly S, Teng J, Becker J-C, Gladman D. Abatacept in psoriatic arthritis: Results of a phase II study. Presented at the ACR/ARHP Annual Scientific Meeting 2009; Abstract 1260.
33. Merrill JTB-V, Westhovens R, Chalmers A, D'Cruz D, Wallace D, Bae S, Sigal L, Becker J, Kelly S, Raghupathi K, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in SLE: Results of a 12-month exploratory study. Presented at the American College of Rheumatology Annual Scientific Meeting 2008; Abstract L15.
34. Linsley PS, Nadler SG. The clinical utility of inhibiting CD28-mediated costimulation. Immunol Rev 2009;229(1): 307-321.
35. Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: An open-label, phase 1 clinical trial. Neurology 2008;71(12): 917-924.
36. SandbornWJ,ColombelJ-F,HanauerS,TarganS,SchreiberS, Bressler B, Raghupathi K, Aranda R, Luo AY. A randomized placebo-controlled trialofabatacept for moderately-to-severely active ulcerative colitis. Presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2009; Abstract 47.
37. Smitten AL, Qi K, Franklin J, Askling J, Lacaille D. Hospitalized infections in the abatacept RA clinical development program: An epidemiological assessment with .10,000 person-years of exposure. Arthritis Rheum 2008;58(S786), Abstract 1674.
38. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 2008;10(2):R45.
39. Smitten A, Simon T, Becker JC. Autoimmune adverse events in the abatacept RA clinical development program: A safety analysis with .10,000 person-years of exposure. Arthritis Rheum 2008;58(S786), Abstract 1673.
40. Grimbacher B, Hutloff A, Schlesier M, Glocker E, Warnatz K, Drager R, Eibel H, Fischer B, Schaffer AA, Mages HW, Kroczek RA, Peter HH. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat Immunol 2003;4(3):261-268.
41. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, Kuchroo VK. The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells. Nat Immunol 2009;10(2):167-175.
42. Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C. Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 2003;111(5):701-706.
43. Dong C, Juedes AE, Temann UA, Shresta S, Allison JP, Ruddle NH, Flavell RA. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409(6816):97-101.
44. Rottman JB, Smith T, Tonra JR, Ganley K, Bloom T, Silva R, Pierce B, Gutierrez-Ramos JC, Ozkaynak E, Coyle AJ. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001;2(7): 605-611.
45. Mesturini R, Nicola S, Chiocchetti A, Bernardone IS, Castelli L, Bensi T, Ferretti M, Comi C, Dong C, Rojo JM, Yagi J, Dianzani U. ICOS cooperates with CD28, IL-2, and IFN-gamma and modulates activation of human naive CD4\+ T cells. Eur J Immunol 2006;36(10):2601-2612.
46. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439(7077):682-687.
47. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11(2):141-151.
48. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291(5502):319-322.
49. Brahmer JR, Topalian S, Wollner I, Powderly JD, Picus J, Drake CG, Covino J, Korman A, Pardoll D, Lowy I. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 2008;26 (May 20 suppl; abstr 3006).
50. Han P, Goularte OD, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004;172(10):5931-5939.
51. Hurchla MA, Sedy JR, Gavrieli M, Drake CG, Murphy TL, Murphy KM. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4 \+ T cells. J Immunol 2005;174(6): 3377-3385.
52. Tao R, Wang L, Murphy KM, Fraser CC, Hancock WW. Regulatory T-cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells. J Immunol 2008;180(10):6649- 6655.
53. Cai G, Anumanthan A, Brown JA, Greenfield EA, Zhu B, Freeman GJ. CD160 inhibits activation of human CD4\+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008;9(2):176-185.
54. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, KaliaV,Subramaniam S,Blattman JN, BarberDL, AhmedR. Molecular signature of CD8 \+ T-cell exhaustion during chronic viral infection. Immunity 2007;27(4):670-684.
55. Abecassis S, Giustiniani J, Meyer N, Schiavon V, Ortonne N, Campillo JA, Bagot M, Bensussan A. Identification of a novel CD160\+ CD4\+ T-lymphocyte subset in the skin: A possible role for CD160 in skin inflammation. J Invest Dermatol 2007;127(5):1161-1166.
56. Oya Y, Watanabe N, Owada T, Oki M, Hirose K, Suto A, Kagami S, Nakajima H, Kishimoto T, Iwamoto I, Murphy TL, Murphy KM, Saito Y. Development of autoimmune hepatitis-like disease and production of auto-antibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008;58(8): 2498-2510.
57. Tao R, Wang L, HanR, Wang T, Ye Q, Honjo T, Murphy TL, Murphy KM, Hancock WW. Differential effects of B and T lymphocyte attenuator and programmed death-1 on accep-tance of partially versus fully MHC-mismatched cardiac allografts. J Immunol 2005;175(9):5774-5782.
58. Truong W, Plester JC, Hancock WW, Merani S, Murphy TL, Murphy KM, Kaye J, Anderson CC, Shapiro AM. Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts. Am J Transpl 2007;7(12):2663-2674.
59. Steinberg MW, Turovskaya O, Shaikh RB, Kim G, McCole DF, Pfeffer K, Murphy KM, Ware CF, Kronenberg M. A crucial role for HVEM and BTLA in preventing intestinal inflammation. J Exp Med 2008;205(6): 1463-1476.
60. Hurchla MA, Sedy JR, Murphy KM. Unexpected role of B and T lymphocyte attenuator in sustaining cell survival during chronic allostimulation. J Immunol 2007;178(10): 6073-6082.
61. Truong W, Hancock WW, Plester JC, Merani S, Rayner DC, Thangavelu G, Murphy KM, Anderson CC, Shapiro AM. BTLA targeting modulates lymphocyte phenotype, function, and numbers and attenuates disease in nonobese diabetic mice. J Leukoc Biol 2009;86(1):41-51.
62. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: Crucial controls of immune tolerance and function. Immunol Rev 2009;229(1):88-100.
63. Lougaris V, Badolato R, Ferrari S, Plebani A. Hyper immunoglobulin M syndrome due to CD40 deficiency: Clinical, molecular, and immunological features. Immunol Rev 2005;203:48-66.
64. Allen RC, Armitage RJ, Conley ME, Rosenblatt H, Jenkins NA, Copeland NG, Bedell MA, Edelhoff S, Disteche CM, Simoneaux DK, Fanslow WC, Belmont J, Spriggs MK. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259(5097): 990-993.
65. Aruffo A, Farrington M, Hollenbaugh D, Li X, Milatovich A, Nonoyama S, Bajorath J, Grosmaire LS, Stenkamp R, Neubauer M, Roberts RL, Noelle RJ, Ledbetter JA, Francke U, Ochs HD. The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome. Cell 1993;72(2):291-300.
66. Conley ME. An evolving view of hyper-IgM syndrome. J Pediatr 1997;131(1 Pt 1):8-9.
67. DiSanto JP, Bonnefoy JY, Gauchat JF, Fischer A, de Saint Basile G. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993;361(6412):541-543.
68. Durandy A, Hivroz C, Mazerolles F, Schiff C, Bernard F, Jouanguy E, Revy P, DiSanto JP, Gauchat JF, Bonnefoy JY, Casanova JL, Fischer A. Abnormal CD40-mediated activation pathway in B lymphocytes from patients with hyper-IgM syndrome and normal CD40 ligand expression. J Immunol 1997;158(6):2576-2584.
69. Korthauer U, Graf D, Mages HW, Briere F, Padayachee M, Malcolm S, Ugazio AG, Notarangelo LD, Levinsky RJ, Kroczek RA. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993;361(6412):539-541.
70. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand. Nature 1995; 378(6557):617-620.
71. Kawabe T, Naka T, Yoshida K, Tanaka T, Fujiwara H, Suematsu S, Yoshida N, Kishimoto T, Kikutani H. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1(3):167-178.
72. Xu J, Foy TM, Laman JD, Elliott EA, Dunn JJ, Waldschmidt TJ, Elsemore J, Noelle RJ, Flavell RA. Mice deficient for the CD40 ligand. Immunity 1994;1(5): 423-431.
73. Orozco G, Eyre S, Hinks A, Ke X, Wilson AG, Bax DE, Morgan AW, Emery P, Steer S, Hocking L, Reid DM, Wordsworth P, Harrison P, Thomson W, Barton A, Worthington J. Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. Ann Rheum Dis 2009; doi:10.1136/ard.2009.109579.
74. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coblyn J, Cui J, Tak PP, Wolbink GJ, Crusius JB, van der Horst-Bruinsma IE, Criswell LA, Amos CI, Seldin MF, Kastner DL, Ardlie KG, Alfredsson L, Costenbader KH, Altshuler D, Huizinga TW, Shadick NA, Weinblatt ME, de Vries N, Worthington J, Seielstad M, Toes RE, Karlson EW, Begovich AB, Klareskog L, Gregersen PK, Daly MJ, Plenge RM. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40(10):1216-1223.
75. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/ CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004;22:307-328.
76. Iezzi G, Sonderegger I, Ampenberger F, Schmitz N, Marsland BJ, Kopf M. CD40-CD40L cross-talk integrates strong antigenic signals and microbial stimuli to induce development of IL-17-producing CD4\+ T cells. Proc Natl Acad Sci USA 2009;106(3):876-881.
77. Jasny E, Eisenblatter M, Matz-Rensing K, Tenner-Racz K, Tenbusch M, Schrod A, Stahl-Hennig C, Moos V, Schneider T, Racz P, Uberla K, Kaup FJ, Ignatius R. IL-12-impaired and IL-12-secreting dendritic cells produce IL-23 upon CD154 restimulation. J Immunol 2008;180(10): 6629-6639.
78. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE, Vaishnaw A. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48(3):719-727.
79. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003; 112(10):1506-1520.
80. Pree I, Wekerle T. New approaches to prevent transplant rejection: Co-stimulation blockers anti-CD40L and CTLA4Ig. Drug Discov Today Therapeut Strat 2006;3(1): 41-47.
81. Langer F, Ingersoll SB, Amirkhosravi A, Meyer T, Siddiqui FA, Ahmad S, Walker JM, Amaya M, Desai H, Francis JL. The role of CD40 in CD40L-and antibody-mediated platelet activation. Thromb Haemost 2005;93(6): 1137-1146.
82. Mirabet M, Barrabes JA, Quiroga A, Garcia-Dorado D. Platelet pro-aggregatory effects of CD40L monoclonal antibody. Mol Immunol 2008;45(4):937-944.
83. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune thrombocytopenic purpura. Br J Haematol 2008;141(4):545-548.
84. Kasran A, Boon L, Wortel CH, Hogezand RA, Schreiber S, Goldin E, Boer M, Geboes K, Rutgeerts P, Ceuppens JL. Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's disease. Aliment Pharmacol Ther 2005;22(2):111-122.
85. Andreakos E, Rauchhaus U, Stavropoulos A, Endert G, WendischV,BenahmedAS, GiaglisS,KarrasJ,LeeS,GausH, Bennett CF, Williams RO, Sideras P, Panzner S. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis. Arthritis Rheum 2009;60(4): 994-1005.
86. GaoD,Wagner AH, Fankhaenel S, StojanovicT, Schweyer S, Panzner S, Hecker M. CD40 antisense oligonucleotide inhibition of trinitrobenzene sulphonic acid induced rat colitis. Gut 2005;54(1):70-77.
87. Kean LS, Gangappa S, Pearson TC, Larsen CP. Transplant tolerance in non-human primates: Progress, current challenges and unmet needs. Am J Transpl 2006;6(5 Pt 1): 884-893.
88. CroftM,So T, DuanW, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009;229(1):173-191.
89. Manku H, Graham DS, Vyse TJ. Association of the co-stimulator OX40L with systemic lupus erythematosus. J Mol Med 2009;87(3):229-234.
90. TamadaK,ShimozakiK,Chapoval AI, ZhaiY,SuJ,Chen SF, Hsieh SL, Nagata S, Ni J, Chen L. LIGHT, a TNF-like molecule, costimulates T-cell proliferation and is required for dendritic cell-mediated allogeneic T-cell response. J Immunol 2000;164(8):4105-4110.
91. Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello RT. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T-cell-dependent B-cell terminal differentiation. Eur J Immunol 2004;34(12):3534-3541.
92. Wan X, Zhang J, Luo H, Shi G, Kapnik E, Kim S, Kanakaraj P, Wu J. A TNF family member LIGHT transduces costimulatory signals into human T cells. J Immunol 2002;169(12):6813-6821. (Pubitemid 36899266)
93. An MM, Fan KX, Zhang JD, Li HJ, Song SC, Liu BG, Gao PH, Zhou Q, Jiang YY. Lymphtoxin beta receptor-Ig ameliorates TNBS-induced colitis via blocking LIGHT/ HVEM signaling. Pharmacol Res 2005;52(3):234-244.
94. Brown GR, Lee EL, El-Hayek J, Kintner K, Luck C. IL-12-independent LIGHT signaling enhances MHC class II disparate CD4\+ T-cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease. J Immunol 2005;174(8):4688-4695.
95. Fava RA, Notidis E, Hunt J, Szanya V, Ratcliffe N, Ngam-Ek A, De Fougerolles AR, Sprague A, Browning JL. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003;171(1): 115-126.
96. Gommerman JL, Giza K, Perper S, Sizing I, Ngam-Ek A, Nickerson-Nutter C, Browning JL. A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. J Clin Invest 2003;112(5):755-767.
97. Pierer M, Schulz A, Rossol M, Kendzia E, Kyburz D, Haentzschel H, Baerwald C, Wagner U. Herpesvirus entry mediator-Ig treatment during immunization aggravates rheumatoid arthritis in the collagen-induced arthritis model. J Immunol 2009;182(5):3139-3145.
98. Wang J, Anders RA, Wang Y, Turner JR, Abraham C, Pfeffer K, Fu YX. The critical role of LIGHT in promoting intestinal inflammation and Crohn's disease. J Immunol 2005;174(12):8173-8182.
99. Fan K, Wang H, Wei H, Zhou Q, Kou G, Hou S, Qian W, Dai J, Li B, Zhang Y, Zhu T, Guo Y. Blockade of LIGHT/ HVEM and B7/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance. Transplantation 2007;84(6):746-754.
100. Scheu S, Alferink J, Potzel T, Barchet W, Kalinke U, Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T-cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J Exp Med 2002;195(12):1613-1624.